

AMENDMENTS TO THE CLAIMS

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims will replace all prior versions and listings of claims in the application:

1-18. (Canceled).

19. (Currently Amended) A method of treating an allergic response to an antigen or allergy related disorder during antigen specific immunotherapy of a subject comprising administering to the subject an amount of a first composition comprising a 5'CpG3' immunostimulatory oligonucleotide that inhibits the allergic response in the subject and a second composition comprising an antigen wherein the first and second compositions are administered in an amount sufficient to modulate the immune response to the antigen, wherein the immunostimulatory oligonucleotide comprises 5' X₁X₂CGX₃X₄ 3', wherein C and G are unmethylated, X₁, X₂, X₃, and X₄ are nucleotides and wherein the immunostimulatory oligonucleotide is 8 to 100 nucleotides in length and at least one internucleotide linkage is a phosphorothioate linkage.

20. (New) The method of claim 19, wherein the oligonucleotide is associated with a nucleic acid delivery complex.

21. (New) The method of claim 20, wherein the nucleic acid delivery complex is a cationic lipid.

22. (New) The method of claim 19, wherein the 5'CpG3' is flanked by two 5' purines and two 3' pyrimidines.

23. (New) The method of claim 19, wherein the oligonucleotide is 8-40 nucleotides in length.

24. (New) The method of claim 19, wherein the oligonucleotide includes at least two unmethylated cytosine-guanine motifs.

25. (New) The method of claim 19, wherein X_3 and X_4 are T.